Fleroxacin was prescribed to treat both HIV-negative and HIV-positive men with proven chancroid in an open study. HIV-negative men were treated with a single 400-mg dose of fleroxacin, and HIV-positive men were treated with 400 mg daily for 5 days. Three of the 58 evaluable HIV-negative men were clinical and microbiologic failures, and two of the 22 evaluable HIV-positive men had persisting infection with Haemophilus ducreyi. Both regimens were well tolerated. Fleroxacin is an acceptable alternative to existing treatment regimens for chancroid in men.

Download full-text PDF

Source

Publication Analysis

Top Keywords

hiv-positive men
12
chancroid open
8
open study
8
hiv-negative men
8
men treated
8
men
7
fleroxacin
4
fleroxacin treatment
4
treatment chancroid
4
study men
4

Similar Publications

An increasing number of treatment guidelines recommend rapid initiation of antiretroviral therapy (ART) after the diagnosis of human immunodeficiency virus (HIV) infection. However, data on the association between rapid ART initiation and alterations in brain structure and function remain limited in people with HIV (PWH). A cross-sectional analysis was conducted on HIV-positive men who have sex with men (MSM) undergoing ART.

View Article and Find Full Text PDF

Objective: This study investigated the efficacy and safety of electrocautery ablation for high-grade squamous intraepithelial lesions (HSILs) in men who have sex with men (MSM) including people with human immunodeficiency virus, using comprehensive biopsy with high-resolution anoscopy (HRA).

Methods: This single-arm, open-label pilot study included 20 MSM with HSIL who were treated with electrocautery ablation. The participants were recruited from the National Center for Global Health and Medicine and followed up using HRA with a comprehensive biopsy approach at 3- and 6-months post-ablation.

View Article and Find Full Text PDF

Objective: To study the heterogeneity and influencing factors of self-acceptance of drug addicts in compulsory isolation in 2 drug rehabilitation centers in Sichuan Province, and to analyze the effects of different types of self-acceptance on subthreshold depression in drug addicts, in order to provide useful references for improving their mental health.

Methods: Self-acceptance Questionnaire (SAQ), Drug use Stereotype Threat Scale(DSTS) and Center for Epidemiologic Studies Depression Scale(CES-D) were used to conduct a questionnaire survey in January 2024 on 1068 drug addicts in two compulsory isolation drug rehabilitation centers in Sichuan Province.

Results: Drug addicts self-acceptance can be categorized into 5 potential categories; men were more likely than women to show lower self-acceptance in the 'low-low'(β = 0.

View Article and Find Full Text PDF

Background: Tenofovir-containing antiretroviral therapy (ART) improves survival in HBV-coinfected people with HIV (PWH). We investigated the incidence of HDV infection and its clinical impact in HBV-coinfected PWH in the era of tenofovir-containing ART.

Methods: Between 2011 and 2022, HBV-coinfected PWH were included and followed until December 2023.

View Article and Find Full Text PDF

In her 2023 report to the United Nations Human Rights Council on digital innovation, technology, and the right to health, the Special Rapporteur on the right to health underscored the positive impact of the digital transformation on young people, but also noted serious concerns, calling for greater efforts to consult and engage with youth and civil society. In our study, early-career researchers from Bangladesh and Colombia collaborated within a broader international research and advocacy project to investigate how diverse young adults experience digital health and to invite their recommendations and collaborative advocacy. Researchers held focus group discussions and interviews with young adults aged 18-30 (in Bangladesh, predominantly men; in Colombia, people living with HIV, gay men, and transgender women).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!